The plant sesquiterpene lactone parthenolide inhibits Wnt/β-catenin signaling by blocking synthesis of the transcriptional regulators TCF4/LEF1

Received for publication, September 21, 2017, and in revised form, January 31, 2018 Published, Papers in Press, February 9, 2018, DOI 10.1074/jbc.M117.819300

Xiaoliang Zhu1†, Chunmao Yuan61, Chenyang Tian6‡, Chen Li, Fen Nie‡, Xiaomin Song‡, Rong Zeng‡, Dianqing Wu∗∗, Xiaojiang Hao6∗∗‡, and Lin Li6∗∗‡

From the 1State Key Laboratory of Molecular Biology, Chinese Academy of Sciences Center for Excellence in Molecular Cell Science, Innovation Center for Cell Signaling Networks, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, University of the Chinese Academy of Sciences, Shanghai 200031, China, the 2State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang 550014, China, the 3State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming 650204, China, the 4School of Life Science and Technology, Shanghai Tech University, 100 Halk Road, Shanghai 201210, China, the 5Key Laboratory of Systems Biology, Chinese Academy of Sciences Center for Excellence in Molecular Cell Science, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031, China, and the 6Vascular Biology and Therapeutic Program and Department of Pharmacology, Yale School of Medicine, New Haven, Connecticut 06520

**Edited by Xiao-Fan Wang

The Wnt/β-catenin pathway is essential for embryonic development and homeostasis, but excessive activation of this pathway is frequently observed in various human diseases, including cancer. Current therapeutic drugs targeting the Wnt pathway often lack sufficient efficacy, and new compounds targeting this pathway are therefore greatly needed. Here we report that the plant-derived natural product parthenolide (PTL), a sesquiterpene lactone, inhibits Wnt signaling. We found that PTL dose-dependently inhibits Wnt3a- and CHIR99021-induced transcriptional activity assessed with the T-cell factor (TCF)/lymphoid enhancer factor (LEF) firefly luciferase (TOPFlash) assay in HEK293 cells. Further investigations revealed that PTL decreases the levels of the transcription factors TCF4/LEF1 without affecting β-catenin stability or subcellular distribution. Moreover, this effect of PTL on TCF4/LEF1 was related to protein synthesis rather than to proteasome-mediated degradation. Of note, siRNA-mediated knockdown of RPL10, a ribosome protein PTL binds, substantially decreased TCF4/LEF1 protein levels and also Wnt3a-induced TOPFlash activities, suggesting a potential mechanism by which PTL may repress Wnt/β-catenin signaling. In summary, PTL binds RPL10 and thereby potently inhibits the Wnt/β-catenin pathway.

Since the first Wnt protein was identified 35 years ago, the Wnt/β-catenin pathway has been well known for its essential role in both embryo development and adult tissue homeostasis (1). In the absence of Wnt signals, cytoplasm β-catenin is phosphorylated by the Ser/Thr kinases GSK3 and CK1. The phosphorylated β-catenin is then recognized and ubiquitylated by β-TRCP and subjected to proteasome-mediated degradation. Upon binding of the Wnt proteins with the membrane receptor Frizzled and LRP5/6, β-catenin is stabilized and shuttled into the nucleus, where it binds to the transcriptional factor TCFs/LEFIα and activates expression of various target genes. Excessive activation of Wnt/β-catenin signaling is frequently observed in a wide range of tumors, such as colorectal cancer, liver cancer, melanoma, prostate cancer, and breast cancer (2), making this pathway an attractive target for cancer therapy. Many efforts have been made to identify and develop drugs that can modulate Wnt/β-catenin signaling, especially by targeting β-catenin and its downstream players (3). Methyl 3-[(4-methylphenyl)sulfonyl]amino]benzoate is a selective inhibitor of Wnt/β-catenin signaling that has been found to bind to β-catenin and induce its proteasome-mediated degradation (4). PNU-74654 and iCRT3 are two other small molecules that inhibit Wnt signaling by disturbing TCF4–β-catenin interaction (5, 6). ICG-001 has been found to compete with CREB-binding protein for binding β-catenin, thereby inhibiting Wnt signaling (7). Our laboratory recently reported NCO43 as a Wnt signaling inhibitor by targeting CARF (collaborator of ARF) to disturb TCF4 and β-catenin interaction (8, 9).

This work was supported by National Key R&D Program of China Grant 2017YFA0503600, National Natural Science Foundation of China Grants 31530094 and 31571456, and Strategic Priority Research Program of the Chinese Academy of Sciences Grants XDB19000000 and XDA12010301. This work was also supported by the Chinese Academy of Sciences/State Administration of Foreign Experts Affairs International Partnership Program for Creative Research Teams. The authors declare that they have no conflicts of interest with the contents of this article.

This article contains Figs. S1–S3 and information.

† These authors contributed equally to this work.

‡ To whom correspondence may be addressed. E-mail: haoxj@mail.kib.ac.cn.

§‡‡ To whom correspondence may be addressed. E-mail: li@sibs.ac.cn.

4 The abbreviations used are: LEF, lymphoid enhancer factor; TCF, T-cell factor; CREB, cAMP-response element-binding protein; PTL, parthenolide; CM, conditioned medium; CHIR, CHIR99021; CHX, cycloheximide; HA, hemagglutinin; FBS, fetal bovine serum; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; TAMRA, tetramethylrhodamine; Ctr, control; DMAPT, dimethylamino-parthenolide.

© 2018 by The American Society for Biochemistry and Molecular Biology, Inc. Published in the U.S.A.
PTL, a sesquiterpene lactone, was first purified from the shoots of the medicinal plant feverfew (Tanacetum parthenium) (10, 11), which is a Chinese folk medical plant and has been used to treat fever, headache, and arthritis for many years (12). In recent years, it has attracted wide attention for its considerable pharmacological activities, including antimicrobial, anti-inflammatory, and especially anticancer effects (13). PTL is well known for its activity of inhibiting NF-κB signaling and is commonly used as an NF-κB inhibitor (14). However, the mechanisms behind the anti-cancer effects of PTL have not been completely understood. Some studies indicate that PTL inhibits tumor growth by increasing reactive oxygen species (ROS) (15, 16). PTL was also found to target epigenetic factors, such as DNMT1 and HDAC1, to inhibit tumor growth (17, 18). Of note, in 2005, PTL was identified as the first small molecule that selectively kills cancer stem cells while sparing normal stem cells in acute and chronic myelogenous leukemia stem cell models (19). After that, the selective killing of cancer stem cells by PTL was also observed in a number of other cancers, such as bone, breast, melanoma, mesenchyme, and prostate cancer (20–25). On the other hand, Wnt/β-catenin signaling is well recognized for its essential role in the maintenance and self-renewal of embryonic and adult stem cells. However, it remains unknown whether PTL may act on Wnt signaling to inhibit tumor growth. In this work, through high-throughput screening, we identified that PTL potently inhibits Wnt3a-induced TOPFlash activity. Further studies indicated that PTL acts through reducing TCF4/LEF1 synthesis via targeting RPL10.

**Results**

**PTL inhibits Wnt/β-catenin signaling in HEK293 cells**

In our high-throughput screening effort for small-molecule compounds modulating Wnt signaling, we identified the small molecule PTL (Fig. 1A). Our results showed that PTL dose-dependently inhibited Wnt3a conditioned medium (CM)–induced TOPFlash reporter activity in HEK293 cells (Fig. 1B). Next we examined the effect of PTL on the expression of Wnt target genes. We treated HEK293 cells with PTL and then carried out real-time PCR. As expected, PTL inhibited expression of the endogenous Wnt target genes *Axin2 and NKD1* in a dose-dependent manner (Fig. 1C). To further explore the structure–activity relationship of PTL, we synthesized a series of PTL derivatives and tested their effects on TOPFlash activity. We found that PTL-4 and PTL-5 exhibited similar inhibitory effects as PTL, whereas PTL-1, PTL-2, PTL-3, PTL-4, or PTL-5 in the presence of either the Ctr CM or Wnt3a CM. Data represent the mean ± S.D. from one experiment. Each experiment was repeated at least three times. **, p < 0.01; ***, p < 0.001; significant relative to vehicle control; ns, no statistical significance.

Figure 1. PTL inhibits Wnt/β-catenin signaling. A, chemical structure of PTL. B, PTL inhibits Wnt/β-catenin signaling in a dose-dependent manner. HEK293 cells were transfected with TOPFlash plasmids. After 18 h of transfection, the cells were treated with DMSO or PTL for 1 h, followed by Wnt3a CM or control (Ctr) CM plus the same dose of PTL for another 6 h and then lysed for luciferase assays. RLC, relative luciferase count. C, PTL inhibits Wnt target gene expression. Expression of the Wnt target genes *NKD1 and Axin2* was determined by quantitative real-time PCR and normalized to GAPDH expression. D, distinct effects of PTL and its derivates on TOPFlash reporter activity. HEK293 cells were treated with DMSO or 20 μM PTL, PTL-1, PTL-2, PTL-3, PTL-4, or PTL-5 in the presence of either the Ctr CM or Wnt3a CM. Data represent the mean ± S.D. from one experiment. Each experiment was repeated at least three times. **, p < 0.01; ***, p < 0.001; significant relative to vehicle control; ns, no statistical significance.
parent molecule that is PTL, it was not surprising to find that PTL-4 inhibits Wnt/β-catenin signaling, as does PTL.

**PTL does not affect β-catenin stability or subcellular distribution**

As mentioned before, β-catenin is the central player of canonical Wnt signaling, and its accumulation and nuclear translocation are hallmarks for activation of the signaling pathway. Thus, we wanted to ask whether PTL affects Wnt signaling through regulating the accumulation of β-catenin. To answer this question, we first tested the effect of PTL on TOPFlash activity induced by a glycogen synthase kinase (GSK) inhibitor, CHIR99021 (26). We transfected HEK293 cells with TOPFlash plasmids, and then we treated cells with CHIR and two doses of PTL. After 1 h, cells were treated with control or Wnt3a CM containing the same dose of PTL for an additional 2 h. The cells were then fractioned as described under “Experimental procedures,” and the samples were analyzed by Western blot analysis. Tubulin was used as a cytosolic marker, and SP1 was used as a nuclear marker. The immunoblots were quantified by densitometry, and the values are given beneath each band. D, immunofluorescence staining shows that PTL does not influence β-catenin protein levels and distribution. HEK293 cells were treated with 10 μM of PTL for 1 h, and then cells were incubated with control or Wnt3a CM containing the same dose of PTL for an additional 2 h. The cells were then fixed as described under “Experimental procedures,” and the images were collected and analyzed by Opera. Scale bars = 50 μm. Data represent the mean ± S.D. from one experiment. Each experiment was repeated at least three times. *, p < 0.05; **, p < 0.01; ***, p < 0.001; significant relative to vehicle control.

“β-catenin destruction complex”. Next we wanted to investigate the activity of PTL in the case of constant β-catenin activation. For this purpose, we used the colon cancer cell lines Caco2 and SW480, which harbor adenomatous polyposis coli (APC) mutations, as well as HCT116 and SW48, which harbor β-catenin mutations. We transfected the plasmids of TOPFlash/FOPFlash to those colon cancer cells, followed by treatment with PTL. As shown in Fig. 2B, PTL efficiently inhibited TOPFlash reporter activity in all four cell lines, indicating that PTL acts downstream of β-catenin accumulation. To further examine the effects of PTL on β-catenin activation, we treated HEK293 cells with two doses of PTL in the presence of either control conditioned medium or Wnt3a conditioned medium. We then separated the cytosol and nucleus of the cells and subjected them to Western blot analysis using β-catenin/tubulin/SP1 antibodies. As shown in Fig. 2C, PTL had no effect on endogenous β-catenin protein levels or its subcellular distribution. Consistent with this result, in an immunofluorescence
assay with a β-catenin-specific antibody, β-catenin levels and its subcellular distribution showed no differences between the PTL-treated and control groups (Fig. 2D). These results further confirm that PTL does not affect β-catenin stability or subcellular distribution.

**PTL decreases TCF4/LEF1 protein levels**

Our results above suggest that PTL acts downstream of β-catenin accumulation and nuclear localization. Thus, PTL very likely acts on the TCF/LEF1 transcriptional factors in the nucleus. To test this possibility, we first examined whether PTL affects TCF/LEF1 protein levels. The human TCF family has four members: TCF1, TCF3, TCF4 and LEF1. Before testing the effect of PTL on TCF family proteins, we measured the mRNA levels of TCF1, TCF3, TCF4, and LEF1 in HEK293 cells. We found that the mRNA levels of TCF4 and LEF1 are much higher (nearly 40- to 50-fold) than that of TCF1 and TCF3 (Fig. S2). Therefore we carried out our further studies on TCF4 and LEF1. HEK293 cells were cultured in control CM or Wnt3a CM with 5 or 10 μM PTL for 6 h. As shown in Fig. 3, A and B, both TCF4 and LEF1 protein levels were reduced by PTL in a dose-dependent manner regardless of Wnt stimulation. PTL also reduced TCF4/LEF1 levels in a time-dependent manner (Fig. 3, C and D). In view of the significant differences in mRNA levels of TCF family members, although the TCF1 and TCF3 protein levels in HEK293 cells were also decreased after PTL treatment, PTL inhibition of Wnt signaling was mainly due to the decrease of TCF4 and LEF1 (Fig. S3). However, there was no difference between the levels of TCF4/LEF1 mRNAs before and after 10 μM PTL treatment in the control conditioned medium, indicating that PTL could not function by regulating the transcription of TCF4/LEF1. Consistent with this, upon Wnt treatment, TCF4 mRNA levels were also not affected by PTL treatment, supporting that PTL does not function through affecting gene transcription (Fig. S2). However, LEF1 mRNA levels were apparently reduced by PTL. This is due to the fact that LEF1 is a target gene of Wnt signaling. Because PTL treatment leads to inhibition of Wnt signaling, it was not surprising to find a decrease of LEF1 mRNA levels by PTL treatment. Thus, this decrease of LEF1 mRNA levels is most likely due to inhibition of Wnt signaling rather than a direct effect on LEF1 transcription by PTL.

**PTL decreases TCF4/LEF1 levels by blocking protein synthesis**

Because our data suggest that PTL does not act through affecting gene transcription, we asked how PTL reduces TCF4/LEF1 protein levels. One possibility is that PTL may facilitate proteasome-mediated degradation of TCF4/LEF1 proteins.
Therefore, we blocked proteasome-induced degradation by using MG132. We treated HEK293 cells with 20 μM MG132 followed by PTL treatment. We found that blocking proteasome-induced degradation with MG132 does not affect PTL activity in decreasing TCF4/LEF1 protein levels (Fig. 4A), indicating that PTL does not act through promoting TCF4/LEF1 degradation. Next we tested whether blocking protein synthesis by using CHX affects the PTL activity of inhibiting Wnt signaling. As shown in Fig. 4B, when protein synthesis process is blocked by CHX, treatment with PTL could not further decrease TCF4/LEF1 levels (Fig. 4B). To further address whether PTL inhibits protein synthesis of TCF4 and LEF1, we carried out a pulldown assay using biotinylated PTL as the bait with or without addition of unlabeled PTL. As shown in Fig. 5C, biotin-PTL captured RPL10, and this binding could be competed off by free PTL, supporting RPL10 as the target of PTL. To examine the role of PRL10 in Wnt signaling, we deprived HEK293 cells of RPL10 using the method of RNAi. As shown in Fig. 5D, knockdown of RPL10 significantly reduced TOPFlash reporter activity. Moreover, RPL10 deprivation led to a marked decrease in TCF4 and LEF1 levels (Fig. 5E). Our results, combined with the findings of Chen et al., confirmed that PTL reduces TCF4/LEF1 protein levels by targeting the ribosome protein RPL10.

**PTL inhibits proliferation of colon cancer cells**

As mentioned before, overactivation of Wnt/β-catenin signaling is closely related to tumor formation and progression. One anecdote is colon cancer. More than 80% of colon cancers harbor mutations in the scaffold protein APC and have overactivated Wnt signaling (28). Thus, we used human colon cancer cells to test the potential of PTL in cancer therapy. We found that PTL significantly reduced TCF4 levels in the colon cancer cell lines SW480, Caco2, and HT29 but has no apparent effects on β-catenin levels in these cells (Fig. 6A). Consistently, PTL inhibited expression of the Wnt target gene NKD1 in these three colon cancer cell lines in a dose-dependent manner (Fig. 6B). A colony-forming assay also showed that PTL inhibited colon cancer cell proliferation at a level similar to its inhibitory activity toward Wnt signaling (Fig. 6C). These results demonstrate the potential of PTL in the treatment of colon cancers that are mostly driven by overactivated Wnt signaling.
The Wnt/β-catenin signaling pathway is one of the most important pathways in development and is involved in many aspects of tumorigenesis. Considerable efforts have been made to identify and develop effective inhibitors against the Wnt signaling pathway. However, successes in finding inhibitors of this pathway are very limited, and so far, no drugs specific for Wnt signaling have been approved for clinical applications. In this study, we investigated the effect of PTL, a small molecule, on Wnt signaling in colon cancer cells.}

Discussion

The Wnt/β-catenin signaling pathway is one of the most important pathways in development and is involved in many aspects of tumorigenesis. Considerable efforts have been made to identify and develop effective inhibitors against the Wnt signaling pathway. However, successes in finding inhibitors of this pathway are very limited, and so far, no drugs specific for Wnt signaling have been approved for clinical applications. In this study, we investigated the effect of PTL, a small molecule, on Wnt signaling in colon cancer cells.
PTL has been reported to specially inhibit cancer stem cell growth without killing normal tissue cells in leukemia and solid tumors (13). Wnt/β-catenin signaling is known to be essential for the maintenance of stem cells (1). Our work shows that PTL inhibits colon cancer cell growth. Whether this inhibition of colon cancer cell growth is caused by inhibition of Wnt/β-catenin signaling in cancer stem cells also warrants further study.

In summary, our study identifies PTL as a new inhibitor of Wnt/β-catenin signaling by targeting RPL10 and blocking TCF4/LEF1 synthesis. Given that DMAPT, a more hydrophilic form of PTL, has been approved for clinical trial for hematologic malignancies, our findings provide proof of concept for the use of PTL as a potential drug for treating Wnt-driven tumors.

**Experimental procedures**

**Isolation of PTL, synthesis of biotin-PTL, and PTL derivatives**

For isolation of PTL, air-dried powdered leaves of Magnolia grandiflora (10.0 kg) were extracted with MeOH (20 liters × 3) under reflux three times (4, 3, and 3 h, respectively) at 80 °C. The combined MeOH extracts were concentrated in a vacuum to give a crude residue (600 g) that was suspended in water. The water layer was successively partitioned with ethyl acetate (EtOAc) (10 liters × 3). The EtOAc portion (220 g) was repeatedly subjected to a silica gel column to get parthenolide (2.0 g). The purity of parthenolide was greater than 95% as determined by TLC and NMR spectra. Biotin-PTL and PTL derivatives were synthesized as described in Fig. S1.

**Antibodies and reagents**

Antibodies for β-catenin (BD Transduction Laboratories), TCF4 (Millipore), LEF1 (Cell Signaling Technology), SP1 (Sigma), tubulin (Sigma), actin (Santa Cruz Biotechnology), and HA (Covance) were utilized in this study. Wnt3a CM and control medium were described previously (36). CHIR-99021 was purchased from Selleckchem. MG132 and CHX were purchased from Sigma-Aldrich. The full-length complementary DNA of human RPL10 was generated by PCR from HEK293 complementary DNA libraries, cloned into the mammalian expression vector pCMV tagged with HA, and verified by DNA sequencing. The siRNA sequences of RPL10 #1 and #2 were 5′-GGCCAAGUUAUCAUGUCCA-3′ and 5′-CUGAUGC-CAAGAUUGC-3′, respectively. The negative control siRNA sequence was 5′-UUCUCGAACGUGUCACGU-3′.

**Cell culture, transfection, and reporter gene assay**

HEK293 cells were cultured in Dulbecco’s modified Eagle’s medium containing 10% FBS. HT29 and HCT116 cells were maintained in McCoy’s 5A medium with 10% FBS. SW480 and SW48 cells were maintained in Leibovitz’s medium with 10% FBS. Caco2 cells were maintained in minimum Eagle’s medium with 20% FBS. Mycoplasma contamination tests were performed for all cells used in this study.

HEK293 cells were transfected by Lipofectamine 2000 (Invitrogen) or RNAiMAX (Invitrogen) according to the manufacturer’s instructions, whereas SW480, Caco2, HCT116, and SW48
Parthenolide inhibits Wnt/β-catenin signaling

cells were transfected by Lipofectamine 3000 (Invitrogen). For reporter gene assays, cells were seeded in 24-well plates. Each well of HEK293 cells was transfected with 250 ng of plasmids in total, including 30 ng of TOPFlash and 25 ng of GFP. The LacZ plasmid was added to equalize the total amount of transfected DNA. After 18 h, the cells were treated with Wnt3a conditioned medium or control medium for another 6 h and then lysed for luciferase assays. Each well of SW480, Caco2, HCT116, and SW48 cells was transfected with 250 ng of plasmids in total, including 50 ng of TOPFlash or FOPFlash, 50 ng of GFP, and 150 ng of LacZ. The cells were lysed for luciferase assays 24 h after transfection. The GFP expression levels were determined for normalization as described previously (37).

Drug treatment and Western blot analysis

Cells were treated with the indicated dose of drugs and harvested with 2× loading buffer (0.3 M Tris-HCl, 10% SDS, 6% β-mercaptoethanol, 50% glycerol, and 0.05% bromphenol blue). Then proteins were separated by SDS-PAGE and blotted onto polyvinylidene difluoride membranes (Millipore). Membranes were blocked with 5% nonfat dry milk for 1 h and then incubated with primary antibodies for 1 h at room temperature or overnight at 4 °C. After being washed, membranes were incubated for 1 h at room temperature with the appropriate horseradish peroxidase–conjugated secondary antibodies (Thermo Scientific) for 1 h. Results were visualized with Tanon 5200.

Cytosol and nucleus fractionation

HEK293 cells were grown in 6-well plates, harvested with a cell scraper into 1.5 ml of PBS, and spun at 700 × g for 10 min. Then the cytosol and nucleus fractions were separated with a nuclear and cytoplasmic extraction kit (CW0199S, CWBIO) according to the manufacturer’s instructions.

Immunofluorescence staining

HEK293 cells were seeded into a 96-well plate to make 6000 cells/well. 48 h later, the indicated dose of PTL was added to the wells for 1 h, followed by Wnt3a conditioned medium or control conditioned medium plus the same dose of PTL for an additional 2 h. Then cells were fixed with 4% paraformaldehyde (Alfa Aesar, 30525894) for 15 min at 4 °C. The fixed samples were incubated with a primary antibody against β-catenin overnight at 4 °C, followed by Cy3-conjugated anti-mouse secondary antibody and 4,6-diamidino-2-phenylindole. For each well, 10 random-field fluorescence images were captured by the Opera LX high-content confocal imaging system with a ×20 Air-LUCPLFLN objective (numerical aperture = 0.45, PerkinElmer Life Sciences) (38).

RT-PCR and quantitative real-time PCR

The total RNA was isolated with a TRizol kit (Invitrogen). Reverse transcription of purified RNA was performed using oligo(dT) priming and Superscript III reverse transcriptase according to the manufacturer’s instructions (Invitrogen). Quantitative real-time PCR for Axin2, NDK1, and GAPDH was performed with the TaKaRa SYBR Premix Ex Taq kit on the ABI PRISM 7500 system (Applied Biosystems). The primers used were human-specific as follows: Axin2, 5′-AGTGTGAG-GTCCACGGAAAC-3′ (forward) and 5′-CTTCACACTCGGATGCATTTT-3′ (reverse); NDK1, 5′-GTCAACACTCCC-AACATC-3′ (forward) and 5′-AATGTGTTAGCAGCAG-3′ (reverse); GAPDH, 5′-AGTCGGAGTCACCGAT-3′ (forward) and 5′-GTAAACCATGTAGTTGGAGTC-3′ (reverse); RPL10, 5′-AGTCGAGAACAAAGGACAT-3′ (forward) and 5′-GTGAAGCCCCACTTCTTGA-3′ (reverse).

Nonradioactive metabolic labeling assay

The nonradioactive metabolic labeling assay mainly includes four parts: nascent protein labeling, immunoprecipitation of the protein of interest (for example, TCF4), Click-iT reaction of the immunoprecipitated protein, and detection of the nascent protein of interest by immunoblotting (39). For nascent protein labeling, HEK293 cells at 80–90% confluency were incubated in complete normal medium with the indicated dose of PTL or CHX for 1 h. Then HEK293 cells were washed once with warm PBS and incubated with methionine-free medium (Thermo Fisher Scientific) together with PTL or CHX for 4 h instead of the traditional [35S]methionine. 4 h later, cells were harvested in lysis buffer (1% SDS in 50 mM Tris-HCl [pH 8.0]) with protease inhibitors. The immunoprecipitation experiment was performed using protein A/G Plus–agarose (Santa Cruz Biotechnology) and antibody against TCF4 (Millipore) or LIF1 (Cell Signaling Technology), following the recommended procedures. The immunoprecipitated TCF4 or LIF1 was further labeled with tetrathymethylrhodamine (TAMRA) azide (Thermo Fisher Scientific) via a copper-catalyzed reaction between azide and l-homopropargylglycine (Thermo Fisher Scientific) with PTL or CHX for 1 h at 4 °C. Then the labeled proteins were detected by standard immunoblotting using an antibody against TAMRA azide (Thermo Fisher Scientific). Of note, the molecular mass of the detected protein should be a bit larger than expected, and the integrated molecular mass should be the molecular mass of TAMRA azide (555 Da) multiplied by the number of methionine residues in the labeled protein, and the labeled protein is probably not recognized by the normal antibody because of the integration of TAMRA azide.

Biotin pulldown assay

HEK293T cells were transfected with HA-tagged RPL10 plasmids. After 24 h of transfection, the cells were lysed with 500 μl of lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 1% (v/v) Triton X-100, and 5 mM EDTA [pH 7.4]) containing protease inhibitors and centrifuged at 16,000 × g for 15 min at 4 °C. 20 μl of the supernatant was used as the input by adding 20 μl of 2× loading buffer, and the remaining 480 μl of supernatant was mixed with biotin-PTL (10 μM) together with streptavidin–agarose (Novex, Carlsbad, CA) at 4 °C for 1 h. For competition experiments, PTL (20 μM) was added to the mixture. The beads
were washed three times and resuspended in 40 μl of 2× loading buffer.

**Colony-forming assays**

For colony formation assays, cells were seeded in 6-well plates (1500 cells/well for Caco2 cells, 2000 cells/well for HT29 cells, and 1000 cells/well for SW480 cells). The cells were treated with control (DMSO) or PTL with medium changes every 3 days until visible colonies formed. At the end of the experiment, cells were washed with PBS twice and fixed with cold methanol for 30 min. After fixation, cells were stained with 2% crystal violet (25% methanol) at room temperature for 1 h. After staining, the plates were rinsed with distilled water and dried.

**Statistical analysis**

An unpaired Student’s t test was used to evaluate the difference between the two treatments. p < 0.05 was considered to be statistically significant, and a p < 0.01 was considered to be extremely statistically significant. Statistical analyses were performed using SYSTAT SigmaPlot 10.0 statistics software.

**Author contributions**—X. Z., C. Y., C. T., C. L., and F. N. conducted the experiments. X. S., R. Z., X. H., D. W., and L. L. analyzed the results. X. Z., C. Y., X. S., and L. L. wrote the manuscript with comments from all authors. L. L. and X. H. guided all aspects of this study.

**Acknowledgments**—We thank the Core Facility of Molecular Biology (Shanghai Institute of Biochemistry and Cell Biology) for providing instrument access and technological backup.

**References**

1. Nusse, R., and Clevers, H. (2017) Wnt/β-catenin signaling, disease, and emerging therapeutic modalities. *Cell* 169, 985–999 CrossRef Medline

2. Clevers, H., and Nusse, R. (2012) Wnt/β-catenin signaling and disease. *Cell* 149, 1192–1205 CrossRef Medline

3. Anastas, J. N., and Moon, R. T. (2013) WNT signalling pathways as therapeutic targets in cancer. *Nat. Rev. Cancer* 13, 11–26 CrossRef Medline

4. Hwang, S. Y., Deng, X., Byun, S., Lee, S. J., Suh, H., Zhang, J., Kang, Q., Zhang, T., Westover, K. D., Mandinova, A., and Lee, S. W. (2016) Direct targeting of β-catenin by a small molecule stimulates proteasomal degradation and suppresses oncogenic Wnt/β-catenin signaling. *Cell Rep.* 16, 28–36 CrossRef Medline

5. Trosset, J. Y., Dalvit, C., Knapp, S., Fasolini, M., Veronesi, M., Mantegani, S., Gianelli, L. M., Catana, C., Sundström, M., Stouten, P. F., and Moll, J. K. (2006) Inhibition of protein-protein interactions: the discovery of druglike β-catenin inhibitors by combining virtual and biophysical screening. *Proteins* 64, 60–67 CrossRef Medline

6. Gonsalves, F. C., Klein, K., Carson, B. B., Katz, S., Elas, A. L., Evans, S., Nagourney, R., Cardozo, T., Brown, A. M., and DasGupta, R. (2011) An RNAi-based chemical genetic screen identifies three small-molecule inhibitors of the Wnt/wingless signaling pathway. *Proc. Natl. Acad. Sci. U.S.A.* 108, 5954–5963 CrossRef Medline

7. Emami, K. H., Nguyen, C., Ma, H., Kim, D. H., Jeong, K. W., Eguchi, M., Moon, R. T., Teo, J. L., Oh, S. W., Kim, H. Y., Moon, S. H., Ha, J. R., and Kahn, M. (2004) A small molecule inhibitor of β-catenin/cyclic AMP response element-binding protein transcription. *Proc. Natl. Acad. Sci. U.S.A.* 101, 12682–12687 CrossRef Medline

8. Wang, W., Liu, H., Wang, S., Hao, X., and Li, L. (2011) A diterpenoid derivative 15-oxospiramilactone inhibits Wnt/β-catenin signaling and colon cancer cell tumorigenesis. *Cell Res* 21, 730–740 CrossRef Medline

9. He, X., Zhang, W., Yan, C., Nie, F., Li, C., Liu, X., Fei, C., Li, S., Song, X., Jia, Y., Zeng, R., Wu, D., Pan, W., Hao, X., and Li, L. (2017) Chemical biology reveals CARF as a positive regulator of canonical Wnt signaling by promoting TCF/β-catenin transcriptional activity. *Cell Discov.* 3, 1703 CrossRef Medline

10. Bohlmann, F., and Zdero, C. (1982) Sesquiterpene lactones and other constituents from *Tanacetum parthenium*. *Phytochemistry* 21, 2543–2549 CrossRef Medline

11. Stojakowska, A., and Kisiel, W. (1997) Production of parthenolide in organ cultures of feverfew. *Plant Cell Tiss. Org.* 47, 159–162 CrossRef Medline

12. Knight, D. W. (1995) Feverfew: chemistry and biological activity. *Nat. Prod. Rep.* 12, 271–276 CrossRef Medline

13. Ghantous, A., Sinjab, A., Herceg, Z., and Darwiche, N. (2013) Parthenolide: from plant shoots to cancer roots. *Drug Discov. Today* 18, 894–905 CrossRef Medline

14. Bork, P. M., Schmitz, M. L., Kuhn, M., Escher, C., and Heinrich, M. (1997) Sesquiterpene lactone containing Mexican Indian medicinal plants and pure sesquiterpene lactones as potent inhibitors of transcription factor NF-κB. *FEBS Lett.* 402, 85–90 CrossRef Medline

15. Wen, J., You, K. R., Lee, S. Y., Song, C. H., and Kim, D. G. (2002) Oxidative stress-mediated apoptosis: the anticancer effect of the sesquiterpene lactone parthenolide. *J. Biol. Chem.* 277, 38954–38964 CrossRef Medline

16. Yang, C., Yang, Q. O., Kong, Q. J., Yuan, W., and Ou Yang, Y. P. (2016) Parthenolide induces reactive oxygen species-mediated autophagic cell death in human osteosarcoma cells. *Cell Physiol. Biochem.* 40, 146–154 CrossRef Medline

17. Liu, Z., Liu, S., Xie, Z., Pavlovicz, R. E., Wu, J., Chen, P., Aimiuwu, J., Pang, J., Bhadin, D., Neviani, P., Fuchs, J. R., Plass, C., Li, P. K., Li, C., Huang, T. H., et al. (2009) Modulation of DNA methylation by a sesquiterpene lactone parthenolide. *J. Pharmacol. Exp. Ther.* 329, 505–514 CrossRef Medline

18. Gopal, Y. N., Azora, T. S., and Van Dyke, M. W. (2007) Parthenolide specifically depletes histone deacetylase 1 protein and induces cell death through ataxia telangiectasia mutated. *Chem. Biol.* 14, 813–823 CrossRef Medline

19. Guzman, M. L., Rossi, R. M., Karmischky, L., Li, X., Peterson, D. R., Howard, D. S., andordan, C. T. (2005) The Sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. *Blood* 105, 4163–4169 CrossRef Medline

20. Zuch, D., Giang, A. H., Shapovalov, Y., Schwarz, E., Rosier, R., O’Keefe, R., and Eliseev, R. A. (2012) Targeting radioresistant osteosarcoma cells with parthenolide. *J. Cell. Biochem.* 113, 1282–1291 CrossRef Medline

21. Zhou, J. B., Zhang, H., Gu, P. H., Bai, J. N., Margolick, J. B., and Zhang, Y. (2008) NF-κB pathway inhibitors preferentially inhibit breast cancer stem-like cells. *Breast Cancer Res. Tr.* 111, 419–427 CrossRef Medline

22. Czyz, M., Kropowska, K., and Szitller-Sikorska, M. (2013) Parthenolide reduces the frequency of ABCB5-positive cells and clonogenic capacity of melanoma cells from anchorage independent melanospheres. *Cancer Biol. Ther.* 14, 135–145 CrossRef Medline

23. Uchibori, R., Tsukahara, T., Mizuguchi, H., Saga, Y., Urabe, M., Mizukami, H., Kume, A., and Ozawa, K. (2013) NF-κB activity regulates mesenchymal stem cell accumulation at tumor sites. *Cancer Res.* 73, 364–372 CrossRef Medline

24. Kawaski, B. T., Hurt, E. M., Kalathur, M., Duhagon, M. A., Milner, J. A., Kim, Y. S., and Farrar, W. L. (2009) Effects of the sesquiterpene lactone parthenolide on prostate tumor-initiating cells: an integrated molecular profiling approach. *Prostate* 69, 827–837 CrossRef Medline

25. Birnie, R., Bryce, S., Roome, C., Dussupt, V., Droop, A., Lang, S. H., Berry, P. A., Hyde, C. F., Lewis, J. L., Stower, M. J., Maitland, N. J., and Collins, A. T. (2008) Gene expression profiling of human prostate cancer stem-like cells. *Breast Cancer Res.* 10, 111, R83 CrossRef Medline

26. Huang, S. M., Mishina, Y. M., Liu, S., Cheung, A., Stegmeier, F., Michaud, G. A., Charlat, O., Wiellette, E., Zhang, Y., Wiessner, S., Hild, M., Shi, X., Kume, A., and Azawa, K. (2013) NS-1260 activity regulates mesenchymal stem cell accumulation at tumor sites. *Cancer Res.* 73, 364–372 CrossRef Medline

27. Shi, C., Wang, Y., Guo, Y., Chen, Y., and Liu, N. (2017) Cooperative down-regulation of ribosomal protein L10 and NF-κB signaling pathway is re-
Parthenolide inhibits Wnt/β-catenin signaling

sponsible for the anti-proliferative effects by DMAPT in pancreatic cancer cells. *Oncotarget* **8**, 35009–35018 Medline

28. Giles, R. H., van Es, J. H., and Clevers, H. (2003) Caught up in a Wnt storm: Wnt signaling in cancer. *Biochim. Biophys. Acta** 1653, 1–24 Medline

29. Schuijers, J., Mokry, M., Hatzis, P., Cuppen, E., and Clevers, H. (2014) Wnt-induced transcriptional activation is exclusively mediated by TCF/LEF. *EMBO J.* **33**, 146–156 CrossRef Medline

30. Franz, A., Shlyueva, D., Brunner, E., Stark, A., and Basler, K. (2017) Probing the canonicity of the Wnt/Wingless signaling pathway. *PLoS Genet.* **13**, e1006700 CrossRef Medline

31. Hrckulak, D., Kolar, M., Strnad, H., and Korinek, V. (2016) TCF/LEF transcription factors: an update from the internet resources. *Cancers (Basel)* **8**, 70 CrossRef Medline

32. Ishiguro, H., Wakasugi, T., Terashita, Y., Sakamoto, N., Tanaka, T., Sагawa, H., Okubo, T., and Takeyama, H. (2016) Nuclear expression of TCF4/TCF7L2 is correlated with poor prognosis in patients with esophageal squamous cell carcinoma. *Cell. Mol. Biol. Lett.* **21**, 5 CrossRef Medline

33. Goudarzi, K. M., and Lindström, M. S. (2016) Role of ribosomal protein mutations in tumor development (review). *Int. J. Oncol.* **48**, 1313–1324 CrossRef Medline

34. Shi, Z., Fujii, K., Kovary, K. M., Gennuth, N. R., Röst, H. L., Teruel, M. N., and Barna, M. (2017) Heterogeneous ribosomes preferentially translate distinct subpools of mRNAs genome-wide. *Mol. Cell* **67**, 71–83.e7 CrossRef Medline

35. Sendoe, A., Dunn, J. G., Rodriguez, E. H., Naik, S., Gomez, N. C., Hurwitz, B., Leverse, J., Dill, B. D., Schramek, D., Molina, H., Weissman, J. S., and Fuchs, E. (2017) Translation from unconventional 5′ start sites drives tumour initiation. *Nature* **541**, 494–499 CrossRef Medline

36. Mao, J., Wang, J., Liu, B., Pan, W., Farr, G. H., 3rd, Flynn, C., Yuan, H., Takada, S., Kimelman, D., Li, L., and Wu, D. (2001) Low-density lipoprotein receptor-related protein-5 binds to Axin and regulates the canonical Wnt signaling pathway. *Mol. Cell* **7**, 801–809 CrossRef Medline

37. Li, L., Yuan, H., Xie, W., Mao, J., Caruso, A. M., McMahon, A., Sussman, D. J., and Wu, D. (1999) Dishevelled proteins lead to two signaling pathways: regulation of LEF-1 and c-Jun N-terminal kinase in mammalian cells. *J. Biol. Chem.* **274**, 129–134 CrossRef Medline

38. Mao, L., Liu, C., Wang, Z., Niu, X., Xue, L., Zhou, Z., Cai, Z., Yu, M., Li, Y., Wu, D., and Li, L. (2016) A genome-wide loss-of-function screening method for minimizing false-negatives caused by functional redundancy. *Cell Res.* **26**, 1067–1070 CrossRef Medline

39. Qu, Y., Olsen, J. R., Yuan, X., Cheng, P. F., Levesque, M. P., Brokstad, K. A., Hoffman, P. S., Oyan, A. M., Zhang, W., Kalland, K. H., and Ke, X. (2018) Small molecule promotes β-catenin citrullination and inhibits Wnt signaling in cancer. *Nat. Chem. Biol.* **14**, 94–101 CrossRef Medline